Brukinsa and Rituxan drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Brukinsa (zanubrutinib) and Rituxan (rituximab). Common drug interactions include vomiting among females and death among males.
The phase IV clinical study analyzes what interactions people have when they take Brukinsa and Rituxan. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.
What is Brukinsa?
Brukinsa has active ingredients of zanubrutinib. eHealthMe is studying from 1,334 Brukinsa users. Check the latest studies of Brukinsa.
What is Rituxan?
Rituxan has active ingredients of rituximab. It is often used in rheumatoid arthritis. eHealthMe is studying from 64,791 Rituxan users. Check the latest studies of Rituxan.
11 people who take Brukinsa and Rituxan together, and have interactions are studied.
What are the common drug interactions of Brukinsa and Rituxan, by gender? *:
female:
- Vomiting
- Death
- Fungal infection
- Nausea (feeling of having an urge to vomit)
- Pneumonia
- Respiratory distress (difficulty in breathing)
male:
- Death
- Abdominal distension
- Nausea (feeling of having an urge to vomit)
- Peripheral swelling
- Platelet count decreased
What are the common drug interactions of Brukinsa and Rituxan, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
- Death
- Fungal infection
- Nausea (feeling of having an urge to vomit)
- Pneumonia
- Respiratory distress (difficulty in breathing)
- Vomiting
30-39:
n/a
40-49:
n/a
50-59:
n/a
60+:
- Death
What are the existing conditions these people have? *
- Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 6 people, 54.55%
- Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 2 people, 18.18%
- Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 18.18%
- Cardiac Disorder: 2 people, 18.18%
- Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 9.09%
- Seasonal Allergy (allergic condition due to certain season): 1 person, 9.09%
- Premenstrual Syndrome: 1 person, 9.09%
- Neoplasm Malignant (cancer tumour): 1 person, 9.09%
- Menopause (end of monthly cycles in women): 1 person, 9.09%
- Immunodeficiency Common Variable: 1 person, 9.09%
* Approximation only. Some reports may have incomplete information.
Do you take Brukinsa and Rituxan?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Brukinsa and Rituxan:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Brukinsa:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Rituxan:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Brukinsa and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Rituxan and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on zanubrutinib and rituximab (the active ingredients of Brukinsa and Rituxan, respectively), and Brukinsa and Rituxan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Agranulocytosis and Atrial Fibrillation/Flutter - 2 seconds ago
- Could Ilaris cause Obsessive-Compulsive Disorder? - 6 seconds ago
- Could Spinraza cause Dyspnea Exacerbated? - 16 seconds ago
- Drug interactions of Bortezomib and Ofloxacin - 17 seconds ago
- Could Tamoxifen Citrate cause Enlarged Heart? - 27 seconds ago
- Drug interactions of Glucagon and Apresoline - 30 seconds ago
- Could Etomidate cause Haematoma? - 32 seconds ago
- Could Ambrisentan cause Foot Deformity? - 36 seconds ago
- Drug interactions of Proamatine and Oxycontin - 37 seconds ago
- Could Riluzole cause Headache? - 38 seconds ago